Skye Bioscience Inc.
SKYE
Skye Bioscience, Inc. is a clinical-stage biotechnology company pioneering next-generation molecules that modulate G-protein-coupled receptors ("GPCRs") to treat obesity, overweight, and metabolic disorders. Our lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 ("CB1") a key GPCR involved in metabolic regulation.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$38M
▼ -110.5% YoY
Op. Margin
–
ROIC
-396.38%
▼ -34.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$31M
▼ -60.5% YoY
Op. Cash Flow (TTM)
-$31M
▼ -70.6% YoY
Net Debt
-$5M
Net Cash Position
Cash & Equiv.
$5M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with SKYE
Skye Bioscience (SKYE) in two numbers
Questions about Skye Bioscience
Does Skye Bioscience (SKYE) pay a dividend?
No. Skye Bioscience (SKYE) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 10 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in SKYE's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing SKYE
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.